Brian Olofsson, MD
Family Medicine · Kankakee, ILNPI 1073604534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 502 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by Novo Nordisk at 25.5% of the total. Reporting peaked in 2021 at $1,569 and has fallen 55.9% since, to $692 in 2025. Among family medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 502 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$890
- Amgen$735
- Lilly USA, LLC$715
- Boehringer Ingelheim$579
- Sanofi-aventis U.S. LLC$465
- plus $3K from 33 others
What the payments were for
- Food & beverage$8,36597%
- Education$2253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 133 | $2,186 |
| AstraZeneca(2 entities) | 53 | $890 |
| Amgen | 41 | $735 |
| Lilly USA, LLC | 44 | $715 |
| Boehringer Ingelheim | 29 | $579 |
| Sanofi-aventis U.S. LLC | 31 | $465 |
| Merck | 30 | $454 |
| GSK | 18 | $338 |
| AbbVie(2 entities) | 18 | $298 |
| Johnson & Johnson | 12 | $240 |
| Novartis | 12 | $198 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $197 |
| E.r. Squibb & Sons, L.L.C. | 7 | $146 |
| Corcept Therapeutics | 7 | $140 |
| Bayer | 7 | $115 |
| Pfizer | 5 | $92 |
| Phathom Pharmaceuticals, Inc. | 4 | $80 |
| Abbott | 3 | $70 |
| Sunovion Pharmaceuticals Inc. | 5 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Mylan Specialty L.p. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Harmony Biosciences LLC | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Dexcom, Inc. | 1 | $36 |
| Almatica Pharma LLC | 2 | $35 |
| Itamar Medical Inc | 1 | $30 |
| Eisai Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Insulet Corporation | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Intuity Medical Inc | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,590 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $162,461 |
| FarxigaDapagliflozin Propanediol | 83 | $76,466 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $69,591 |
| JardianceEmpagliflozin | 43 | $58,142 |
| EliquisApixaban | 55 | $51,382 |
| MounjaroTirzepatide | 42 | $45,961 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $45,255 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $22,306 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $21,024 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $17,530 |
| RybelsusSemaglutide | 17 | $17,349 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $17,159 |
| TrulicityDulaglutide | 15 | $16,142 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $11,253 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,186 | $179,810156 claims |
| AstraZenecaFarxiga, Symbicort | $890 | $78,94295 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $579 | $70,53168 claims |
| Lilly USA, LLCMounjaro, Trulicity | $715 | $62,10457 claims |
| PfizerEliquis, Paxlovid | $92 | $54,27069 claims |
| GSKTrelegy Ellipta | $338 | $45,25557 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $465 | $17,53012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Kankakee
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.